Biogen Inc. (LON:0R1B)
London · Delayed Price · Currency is GBP · Price in USD 149.78
+0.95 (0.64%)
At close: Oct 24, 2025
Biogen Employees
Biogen had 7,605 employees as of December 31, 2024. The number of employees increased by 35 or 0.46% compared to the previous year.
Employees
7,605
Change (1Y)
35
Growth (1Y)
0.46%
Revenue / Employee
959.48K GBP
Profits / Employee
146.89K GBP
Market Cap
16.54B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7,605 | 35 | 0.46% |
| Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
| Dec 31, 2022 | 8,725 | -885 | -9.21% |
| Dec 31, 2021 | 9,610 | 510 | 5.60% |
| Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Spire Healthcare Group | 15,703 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
Biogen News
- 1 day ago - Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease - GlobeNewsWire
- 3 days ago - Biogen's Immunology Pipeline Has Long-Term Potential: Analyst - Benzinga
- 3 days ago - Biogen (BIIB) Secures Licensing Deal for Immunology Candidate - GuruFocus
- 3 days ago - Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key - Nasdaq
- 3 days ago - Biogen, Vanqua ink licensing deal worth up to $1B for immunology drug - Seeking Alpha
- 3 days ago - Biogen (BIIB) Secures Global Rights in $1.06 Billion Deal with Vanqua - GuruFocus
- 3 days ago - Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion - Reuters
- 3 days ago - Biogen Inks License Deal For Vanqua Bio's Oral C5aR1 Antagonist - Nasdaq